Study: Drug therapy for Alzheimer's patients deemed cost effective

Share this article:

Treating patients with moderately severe to severe Alzheimer's disease with the drug memantine is more cost-effective than no therapy, according to a European study in the journal Clinical Drug Investigation. Lundbeck SA, Paris, which markets the memantine as Ebixa, provided funding for the study.

Dr. Clement Francois, from Lundbeck SA, and colleagues estimated the cost implications of using memantine relative to no drug therapy over a five-year-period in patients with moderate to severe Alzheimer's disease in Finland.

"Memantine therapy was associated with approximately four extra months of independence, one additional month of residence in the community, and a cost reduction relative to placebo of approximately 1,700 euros [$2,000] per patient over 5 years," the authors write. The figures were based on 2001 costs.

Forest Laboratories sells memantine under the trade name Namenda in the United States. Merz Pharma GmbH of Germany markets it as Axura.

Share this article:

More in News

'Minor' issues at the nursing home can cause disastrous care transitions, expert warns

'Minor' issues at the nursing home can cause ...

What may appear to be minor administrative problems in a nursing home - a fax machine locked away at night or no one designated to copy paperwork - can cause ...

Long-term care facilities approach 80% worker flu vaccination rate after handing power ...

Fourteen long-term care facilities in Pennsylvania dramatically increased their staff flu vaccination rate by having a regional pharmacy take over the process, according to a report issued Thursday by the Agency for Healthcare Quality and Research (AHQR).

RACs were 'most improved' healthcare auditors for getting back money in 2013, ...

Medicare Recovery Audit Contractors dramatically stepped up their overpayment recoveries last year, returning nearly $487 million more to the government than they did in 2012, according to a new report from a federal watchdog agency.